222 results about "Total dose" patented technology

A generic treatment protocol is disclosed for therapeutically treating a patient via an implantable treatment device. Treatment steps can be defined to start and end at absolute times, or can be programmed via telemetry to start a certain amount of time after termination of a previously executed treatment step. Treatment steps have a treatment rate or dose attribute and a duration attribute. Treatment steps may optionally enable patient-activated bolus overlays. Patient-activated rate or dosage adjustments can also optionally be enabled. Repeated-execution treatment-step groups are also provided. Such treatment-step groups can have start and end times, a group duration, and a group total dose, each defined in a manner similar to that for a treatment step. Treatment-step groups include a repetition count, which could be set to a value that causes the group to repeat forever. Single execution treatment steps can, accordingly, be programmed to execute before and/or after a repeated-execution treatment-step group.

A method for treating acute ischemic stroke in a human comprises administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about 0.015 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes, or (b) a bolus. Also described are kits for carrying out this method.

A method and apparatus delivers pulsed laser energy to a damage-sensitive surface. The pulse scanning method and apparatus allow for the deposition of a total dose of laser radiation that could not be attained by any conventional means without damaging the substrate being exposed. Using a solid-state diode pumped YAG laser and an enclosure with a gas ambient, laser pulses are scanned across a substrate according to one of several programmed approaches. Pulses are deposited that are non-adjacent in time, or non-adjacent in space, or both; conventional methods have the pulses adjacent in both time and space. Using the various approaches of the invention, the degree of spatial and temporal adjacency can be precisely controlled to permit significant laser radiation doses without causing any substrate damage. The present invention novel method and apparatus can be carried out by integrating a computer, laser and scan head with a small chamber into which gas can flow to permit a variety of surface reactions on damage-sensitive substrates that could otherwise not be conducted with conventional methods and systems.

A drug infusion system capable of delivering a fluid medication to a patient under direction of a medical professional continually at a basal rate and at an interval rate in each of a plurality of time slots over a specified period of time. The total dose of the fluid medication to be delivered to the patient over the period of time based on the basal rate and the interval rate for each of the plurality of time slots is determined, compared the total dose against a maximum dose. The basal rate is adjusted, if necessary, so that the total dose does not exceed the maximum dose.

Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and/or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg/kg/daily, preferably 0.5-50 mg/kg/daily, and most preferably 1-10 mg/kg/daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg and/or by continuous intravenous infusions between 10 mg/day and 500 mg/day.

Brachytherapy dose attributable to a brachytherapy source is computed for portions of a patient treatment volume corresponding to a pathological target volume and critical structures. Patient image data is accessed to derive a material voxel array. Multiple computation grids are derived. Primary particle fluence is computed for each first grid element using a ray tracing process from which a primary dose and a first scattered particle source are derived. Scattered particle fluence of the first scattered particle source is derived for each second grid element from which a secondary dose is derived. Each first grid element corresponds to a plurality of second grid elements. Primary dose and scattered dose combine to provide total dose at specific volumes. Brachytherapy source models and non-anatomical body surface models may be applied as applicable.

A system for providing a simulated total dose exposure measurement during a nuclear facility training exercise by locating participants using a real time location system, modeling incremental exposure as a function of location and summing incremental exposure to produce a total dose for each of the participants. Total dose may be displayed via a wireless link to a simulated dosimiter worn by each participant. Radiation sources may also have location tags and the exposure model may be modified in real time according to the tracked location of the radiation source. In one embodiment, the locating technology comprises near field locating technology based on comparing near field signal characteristics. Alternative locating technologies may be used.

Formulations and methods of use thereof for restoring neuronal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg/kg/daily, preferably 0.5-50 mg/kg/daily, and most preferably 1-10 mg/kg/daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg, and/or by continuous intravenous infusions between 10 mg/day and 500 mg/day.

A device modeling method in relation to total dose radiation, wherein firstly, an original electronic device is designed and undergoes testing and model extraction to obtain the model of the original device, secondly, the obtained original device undergoes radiation at different target cumulative doses and model extraction to obtain the device model after radiation at all target cumulative doses, and lastly, the obtained original device model and the device model that has received radiation at all target cumulative doses jointly constitute the device model in relation to total dose radiation. Through testing and parameter extraction of the original device and the device that has received radiation at all target cumulative doses, the present invention provides a method for accurate modeling of hardened devices and unhardened devices. Meanwhile it adds radiation dose as a variable into the realization method of device model so that the performance of the circuit that has received radiation at different doses can be accurately predicted through simulation, thus raising the design efficiency and success rate of the circuits.

The invention provides an anti-total-dose shielding device, which comprises a first low Z layer, a high Z layer and a second low Z layer, wherein the first low Z layer is used for moderating and shielding primary electrons, the high Z layer is used for scattering electrons and absorbing secondary bremsstrahlung photons, and the second low Z layer is used for absorbing photoelectrons and back scattered electrons generated in high Z materials and restraining secondary photoelectron emission and electron back scattering generated by action of X-rays and materials. The first low Z layer is the outmost layer and close to the space outside a satellite, and the second low Z layer is the innermost layer and close to a component to be shielded. The first low Z layer and the second low Z layer are made of materials formed by elements of atomic numbers smaller than or equal to 30. The thickness of the first low Z layer ranges from 1 to 3mm, and the thickness of the second low Z layer ranges from 0.2 to 0.4mm. The high Z layer is made of materials formed by elements of atomic numbers larger than or equal to 50, and the thickness of the high Z layer ranges from 0.1 to 0.3mm.

A medication delivery device (MDD) (e.g., injection pen, wearable pump) is paired with an external device (e.g., smart phone, iPad, computer) via wireless link or wireline connection. The MDD provides to the external device captured data from the flow sensor relating to medicine delivery to a patient to ensure complete delivery and minimize MDD misuse or malfunction or inaccuracies in dosing. The MDD can have Bluetooth™ and/or near field communication (NFC) communication circuits for proximity-based pairing and connectivity with the external device for real-time or deferred transfer of captured data to the external device, depending on memory and power availability at the MDD. The MDD or external device can use captured data and corresponding time stamps to determine flow infomatics such as flow rate, total dose delivered, and dose completion status. An LED on the MDD indicates states such as powered on, paired, delivery in progress and delivery completion.

The invention relates to a method for testing the influence of total dose irradiation on the PMOSFET negative bias temperature instability. The method includes test sample grouping and test parameterselection; the total dose irradiation and annealing tests of the test sample; and the negative bias temperature instability measurement of the test sample. In order to ensure the consistency and accuracy of the test result, the sample is divided into a pre-irradiation group, a comparison group and two pre-test groups, and on the basis of the pre-test, the total dose irradiation and annealing testsare carried out on the pre-irradiation group under the determination condition, the comparison group and the pre-irradiation group are subjected to a negative bias temperature instability test underthe same condition, and the test result is compared, the influence of the total dose irradiation on the negative bias temperature instability of the sample is obtained. The method provided by the invention can represent the influence of the total dose irradiation on the negative bias temperature instability of a P-channel metal oxide semiconductor field effect transistor.

A dosage form is disclosed comprising means for delivering essentially a total dose of drug.

In an x-ray imaging method, the acquisition of a signal image is split off into acquisition of two or more subimages or frames. The first subimage may be acquired with an exposure of a low dose followed by a readout cycle. The dose of the exposure for acquiring the first subimage can be chosen such that it is below the default dose for a particular anatomy. The first subimage may be used to calculate or estimate the parameters of exposure for acquiring a second or subsequent images subimage. The estimation may be such that the total dose received by the imager, in acquiring the first and second subimages, achieves an expected target value to provide an image of good quality. The first and second subimages can be combined to form the final image. A detector array supporting automatic exposure control (AEC) includes AEC pixels providing AEC signals. The AEC pixels are independently or individually addressable and/or readable.

The invention discloses an anti-total dose radiation double-edge hardened layout structure which prevents edge electric leakage. The layout structure comprises an active region, an implantation region as well as a field oxide region and a field oxide gate which are outside the active region, overlap section of the active region and the implantation region form a source region and a drain region; the gate is a double-edge structure the two sides of which is beyond the active region, the gate separates the source region from the drain region, the region covered by the gate between the source region and the drain region is a channel region, and a non-implantation active region is arranged between the channel region and the field oxide region which is covered by the gate. The anti-total dose radiation double-edge hardened layout structure can suppress parasitic leakage on device edges caused by the total dose radiation effect with less area cost, and realizes high integration level.